Test Code CHFXH Chromosome Analysis, Hematologic Disorders, Fixed Cells
Reflex Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
_ML20 | Metaphases, 1-19 | No, (Bill Only) | No |
_M25 | Metaphases, 20-25 | No, (Bill Only) | No |
_MG25 | Metaphases, >25 | No, (Bill Only) | No |
_STAC | Ag-Nor/CBL Stain | No, (Bill Only) | No |
Testing Algorithm
This test only includes a charge for professional interpretation of results and does not include charges for analysis.
Analysis charges will be incurred for total work performed, and generally include 2 banded karyograms and the analysis of 20 or more metaphase cells for this test. If no metaphase cells are available for analysis, no analysis charges will be incurred. If additional analysis work is required, additional charges may be incurred. See the Method Description for specific details.
For more information see:
-Acute Promyelocytic Leukemia: Guideline to Diagnosis and Follow-up
-Bone Marrow Staging for Known or Suspected Malignant Lymphoma Algorithm
-Multiple Myeloma: Laboratory Screening
-Myeloproliferative Neoplasm: A Diagnostic Approach to Bone Marrow Evaluation
Method Name
Chromosome Analysis
Specimen Type
VariesNecessary Information
A pathology and/or flow cytometry report may be requested by the Genomics Laboratory to optimize testing and aid in interpretation of results.
Provide a reason for testing and specimen type with each specimen. The laboratory will not reject testing if this information is not provided, but appropriate testing and interpretation may be compromised or delayed.
Specimen Required
Specimen Volume: 2 mL
Additional Information: Advise Express Mail or equivalent if not on courier service.
Specimen Minimum Volume
1 mL
Specimen Stability Information
Specimen Type | Temperature | Time |
---|---|---|
Varies | Ambient (preferred) | |
Refrigerated |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Clinical Information
Chromosomal abnormalities play a central role in the pathogenesis, diagnosis, and treatment monitoring of many hematologic disorders. Cytogenetic studies on bone marrow may be helpful in many malignant hematologic disorders as the observation of a chromosomally abnormal clone may be consistent with a neoplastic process.
Certain chromosome abnormalities may help classify a malignancy. As examples, the Philadelphia (Ph) chromosome, also referred to as der(22)t(9;22)(q34;q11.2), is usually indicative of chronic myeloid leukemia (CML) or acute leukemia, t(8;21)(q22;q22) defines a specific subset of patients with acute myeloid leukemia, and t(8;14)(q24.1;q32) is associated with Burkitt lymphoma.
Cytogenetic studies are also used to monitor patients with hematologic neoplasia and may identify disease progression, such as the onset of blast crisis in CML, which is often characterized by trisomy 8, isochromosome 17q, and multiple Ph chromosomes.
Reference Values
An interpretative report will be provided.
Day(s) Performed
Monday through Friday
Report Available
10 to 11 daysPerforming Laboratory

CPT Code Information
88291- Interpretation and report
88264 w/ modifier 52-Chromosome analysis with less than 20 cells (if appropriate)
88264-Chromosome analysis with 20 to 25 cells (if appropriate)
88264, 88285-Chromosome analysis with greater than 25 cells (if appropriate)
88283-Additional specialized banding technique (if appropriate)